BiVictriX Therapeutics Plc (LON:BVX – Get Free Report) shares were up 17.6% on Tuesday . The stock traded as high as GBX 10 ($0.13) and last traded at GBX 10 ($0.13). Approximately 1,538,020 shares were traded during mid-day trading, an increase of 1,320% from the average daily volume of 108,326 shares. The stock had previously closed at GBX 8.50 ($0.11).
BiVictriX Therapeutics Stock Performance
The stock has a market capitalization of £8.25 million, a P/E ratio of -250.00 and a beta of -0.73. The firm has a 50-day moving average of GBX 9.26 and a 200 day moving average of GBX 10.98. The company has a quick ratio of 7.49, a current ratio of 4.40 and a debt-to-equity ratio of 8.81.
Insider Buying and Selling
In other news, insider Robert Edward Hawkins bought 20,000 shares of BiVictriX Therapeutics stock in a transaction that occurred on Friday, August 30th. The stock was purchased at an average cost of GBX 7 ($0.09) per share, with a total value of £1,400 ($1,817.71). 42.56% of the stock is owned by company insiders.
About BiVictriX Therapeutics
BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia, as well as develops BVX002 and BVX003 for various blood cancers and solid tumours.
See Also
- Five stocks we like better than BiVictriX Therapeutics
- What is the Nasdaq? Complete Overview with History
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- How to Buy Cheap Stocks Step by Step
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- What is a Secondary Public Offering? What Investors Need to Know
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for BiVictriX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiVictriX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.